louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00732446: Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis
Official title: An Evaluation of the Safety and Efficacy of the Administration of a Fixed Combination of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops Compared With the Individual Administration of Moxifloxacin 0.5% and Dexamethasone 0.1% in the Treatment of Bacterial Ocular Inflammation and Infection (Blepharitis and/or Keratitis and/or Conjunctivitis)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Blepharitis
Conjunctivitis
Keratitis
Keywords: moxifloxacin
dexamethasone
ocular inflammation
ocular infection
Lead sponsor: Federal University of São Paulo
Sponsor class: OTHER
Collaborators: name: Alcon Research
First posted: 2008-08-12
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Safety and efficacy of antibiotic steroid combination compared with individual administration in the treatment of bacterial ocular inflammation and infection (blepharitis and/or keratitis and/or conjunctivitis).

Detailed description: Antibiotic/steroid combination compared to individuals components 8 days of treatment.

Eligibility criteria: Inclusion Criteria:

* Patients with diagnosis of blepharitis and/or keratitis and/or bacterial conjunctivitis

Exclusion Criteria:

* Uncontrolled glaucoma or intraocular hypertension
* Wear contact lens during the study
* Patients with sight in a single eye
* Suspicious of viral, fungic infection
* Use of any other ophthalmic drugs during the study
* Use of immunosuppressant therapy
* Known or suspected allergy or hypersensibility to any component of study medication

Primary outcomes:
measure: Evaluation of ocular sign/symptoms (hyperemia on bulbar conjunctiva, palpebral conjunctiva, conjunctival exsudates, palpebral erythema at final visit (Day 8)
timeFrame: Day 8
Secondary outcomes:
measure: Evaluation of sign and symptoms of blepharitis and/or keratitis and/or bacterial conjunctivitis
timeFrame: Day 8
Other outcomes:
Locations:
city: sao Paulo
country: Brazil
facility: Federal University of Sao Paulo
state: SP
Study officials:
affiliation: Federal University of São Paulo
name: Rubens Belfort, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00616746: Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans
Official title: Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Alcohol Consumption
Tobacco Use
Keywords: Alcohol, nicotine
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: VA Connecticut Healthcare System
First posted: 2008-02-15
Enrollment: 18
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is to characterize the interactive effects of acute intravenous (IV) alcohol and nicotine administration in male and female smokers and nonsmokers who use alcohol.


Eligibility criteria: Inclusion Criteria:

* Male or Female, 21 to 50 years old.

Exclusion Criteria:

* Alcohol or Nicotine Naive

Primary outcomes:
measure: Behavioral and Cognitive Measures
timeFrame: Baseline and Test Day
Secondary outcomes:
Other outcomes:
Locations:
city: West Haven
country: United States
facility: VA Connecticut Healthcare System, West Haven Campus
state: Connecticut
Study officials:
affiliation: Yale University
name: Deepak C D'Souza, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01135446: Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
Official title: Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type 2 Diabetes
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: Bristol-Myers Squibb
First posted: 2010-06-02
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single oral doses of 0.001 mg to 2.5 mg dapagliflozin in healthy subjects.


Eligibility criteria: Inclusion Criteria:

* Healthy men and women
* WOCBP who are using acceptable method of contraception
* Women who are not nursing

Exclusion Criteria:

* History of GI disease
* Any GI surgery that could impact study drug absorption
* Glucosuria at screening or Day -2
* Abnormal liver function tests (ALT, AST or total bilirubin \> 10% above ULN)
* History of current or recurrent UTI
* History of Diabetes Mellitus
* History of chronic or recurrent vulvovaginal mycotic infections
* Estimated creatinine clearance (ClCr) \< 80 mL/min using Cockroft-Gault formula
* History of allergy to SGLT2 inhibitors or related compounds

Primary outcomes:
measure: Total 24-hour Urinary Glucose Excretion as a Measure of Pharmacodynamic Effect
timeFrame: 24 hours after dosing
Secondary outcomes:
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: 24 hours after dosing
measure: Dapagliflozin and Dapagliflozin 3-O-glucuronide (Metabolite of Dapagliflozin) Concentrations to Characterize Dapagliflozin Pharmacokinetics
timeFrame: 2 days after dosing
Other outcomes:
Locations:
city: Austin
country: United States
facility: Ppd Development, Lp
state: Texas
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT06566846: Lumbosacral Transitional Vertebra Prevalence Among Egypt Population and Its Association With Lumbar Degeneration
Official title: Lumbosacral Transitional Vertebra(LSTV ) Prevalence in Egypt Population and Its Association With Lumbar Degeneration :Retrospective Evaluation of Consecutive Abdominal CT Scans
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Lumbosacral Anomalies
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-08-22
Enrollment: 500
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study will include all patients underwent KUB CT in Assuit university hospital at one year.

Brief summary: retrospective cross sectional study Study Setting: Cases will be recruited from the recorded data system at the department of diagnostic radiology, Assiut University.

Detailed description: * Study subjects:

  1. Inclusion criteria:

     * All patients underwent MSCT KUB from 2022 till 2023
     * Age between 20-50 years old
  2. Exclusion criteria:

     * All cases below 20 and above 50 .
     * previous history of lumbar spine surgery;
     * non-degenerative pathologies in the lumbar spine which could interrupt the evaluation of lumbar spine degeneration, including spinal tumors, infections, and traumatic fractures;
     * images with poor quality
  3. Sample Size Calculation:

     The study will include all patients underwent KUB CT in Assuit university hospital.

     Objective of this research study will be accomplished through the following consecutive steps:
* Patient Enrolment and sample collection:

Sample are patients underwent MSCT KUB at our hospital , ASSUIT university at one year. Lumbosacral spine will be assessed for LSTV ,the patient images will be divided into two groups ,one which has LSTV as cases and other group with normal spine as control. both groups will be assessed for associated disc degeneration ,facet arthropathy sacroiliac joint degeneration ,paravertebral muscle volume and will be compared with control.

Eligibility criteria: Inclusion Criteria:

* • All MSCT KUB studies from 2022 till 2023

  * age between 20-50

Exclusion Criteria:

* All cases below 20 and above 50 .
* previous history of lumbar spine surgery;
* non-degenerative pathologies in the lumbar spine which could interrupt the evaluation of lumbar spine degeneration, including spinal tumors, infections, and traumatic fractures;
* images with poor quality

Primary outcomes:
measure: prevalence
timeFrame: one year
Secondary outcomes:
measure: correlation of LSTV with lumbar disc degeneration
timeFrame: one year
measure: correlation of LSTV with facet joint arthropathy
timeFrame: one year
measure: correlation of LSTV with sacroiliac degeneration
timeFrame: one year
measure: correlation of LSTV with paravertebral muscle volume
timeFrame: one year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03636646: Analysis of the Posterior Wall Fracture of the Acetabulum
Official title: Analysis of the Posterior Wall Fracture of the Acetabulum
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acetabular Fracture
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2018-08-17
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients of both sexes with posteriir acetabular wall fractures

Brief summary: Assessement,evaluation of postoperativ reduction of posterior wall acetabular fractures in Assiut University Hospital

Detailed description: Posterior wall fracture of the acetabulum resemble 30% of acetabular fracture,surgical treatement is the 1st choice now for most of these fractures as it aimes to restore joint conjuroity and decreases the possibelities of osteoarthrities of the hip joint,in this study investigators will make analysis and assessement of the quality of postoperative reduction which is the main indicator of outcome of acetabular fractures in adult patients in Assiut University Hospitsls

Eligibility criteria: Inclusion Criteria:

* adult patients of both sexes with posterior acetabular wall fracture either isolated or associated with other fractures

Exclusion Criteria:

* other types of acetabular fractures not associated with posterior wall fracture

Primary outcomes:
measure: Analysis of the posterior wall fractures of the acetabulum
timeFrame: Basline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00607646: Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus
Official title: Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 3
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Type 1 Diabetes
Keywords: hypoglycemia
dehydroepiandrosterone
Lead sponsor: University of Maryland, Baltimore
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2008-02-06
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: Elevations of plasma cortisol, a stress hormone, during prior episodes of low blood sugar (hypoglycemia) appear to be responsible for the deficient responses during subsequent hypoglycemia. Our specific aim is to determine if dehydroepiandrosterone (DHEA), a hormone with anti-corticosteroid actions, can prevent hypoglycemia associated autonomic failure in type 1 diabetic volunteers.

Detailed description: DHEA is the acronym for dehydroepiandrosterone, a steroid hormone produced naturally from cholesterol in the adrenal glands of males and females. It is also sold as an over-the-counter dietary supplement, and seems to have anticorticosteroid effects. DHEA antagonizes the effects of corticosterone on hippocampal function in rats and reduces responses to neural stress in mice. In our lab we have found that administration of the DHEA to rats during antecedent hypoglycemia, preserves counter-regulatory responses to subsequent hypoglycemia. The purpose of this study is to determine if the same response occurs in humans.

Eligibility criteria: Inclusion Criteria:

* 28 (14 males, 14 females) Healthy volunteers aged 18-45 yr.
* 28 (14 males, 14 females) Type 1 diabetic patients aged 18-45 yr.
* HbA1c \< 11.0%
* Has been diagnosed Type 1 DM
* No major diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc)
* Body mass index \< 40kg/m-2

Exclusion Criteria:

- pregnancy

Medical history-

* Hepatic Failure/Jaundice
* Renal Failure
* Acute Cerebrovascular/ Neurological deficit

Physical Exam-

* Pneumonia
* Fever greater than 38.0 C
* Blood labs according to protocol

Primary outcomes:
measure: Change in level of catecholamines in blood from baseline
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: University of Maryland, Baltimore
state: Maryland
Study officials:
affiliation: University of Maryland, Baltimore
name: Stephen N. Davis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04709146: The Influence of Covid-19 on the Audio-vestibular System
Official title: The Influence of Covid-19 on the Audio-vestibular System
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Covid19
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2021-01-14
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: the study's porpuse is to examine whether Covid-19 causese a reduction in sensorineural hearing and vestibular function in recovered pateints - compared to healthy controls.

Both study groups will undergo audiometry, tympanometry, Video Head Impulse testing, Subjective Visual Vertigo testing and Video-Nystamography.

Previous audiometry results will also be aquired.


Eligibility criteria: Inclusion Criteria:

* ages 18-80 performed audiometry testing in the last two years

Exclusion Criteria:

* known inner ear dysfunction - Sudden sensorineural hearing loss; autoimmune disease (Cogan's syndrom, SLE, ect.), familial/genetic sensorineural hearing loss, excessive noise exposure.

knowm conductive hearing loss (Air-bone gap\>10dB) prior ear surgery chronic tympanic membrane perforation.

Primary outcomes:
measure: sensoneural hearing level - PTA
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: vestibular function
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05704946: The Effect of Lavender Inhalation on Sleep Quality in Individuals With Coronary Heart Disease
Official title: The Effect of Lavender Inhalation on Sleep Quality in Individuals With Coronary Heart Disease: a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nursing Caries
Lead sponsor: Cukurova University
Sponsor class: OTHER
First posted: 2023-01-30
Enrollment: 61
Sex: ALL
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The study is planned to be conducted as a two-group randomized controlled trial to determine the effect of lavender inhalation on individuals with coronary heart disease. Research data will be collected at Çukurova University Medical Faculty Balcalı Hospital Cardiology Clinic between January-June 2023. In the study, at least 56 samples were found to be sufficient for the sample size. The data of the study will be collected using the Personal Information Form and the Pittsburg Sleep Quality Index.


Eligibility criteria: Inclusion Criteria:

* Able to understand and speak Turkish,
* Who agreed to participate in the research

Exclusion Criteria:

* People with communication difficulties and mental retardation
* People with coagulation disorders
* People with migraines and chronic headaches
* People with an allergy to lavender (Lavandula angustifolia Mill)
* It is the desire to leave the research.

Primary outcomes:
measure: Effect of lavender inhalation on sleep quality
timeFrame: one months
Secondary outcomes:
Other outcomes:
Locations:
city: Adana
country: Turkey
facility: Çukurova University Institute of Health Sciences
Study officials:
References:
Clinical trial NCT00229346: Fibromyalgia and Psychiatric Symptoms Among PMS and PMDD Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Premenstrual Syndrome
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2005-09-29
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: RETROSPECTIVE

Brief summary: Assessing FM and psychiatric disorder in patients suffering from PMS or PMDD


Eligibility criteria: Inclusion Criteria:

* PMDD
* PMS
* Referral to gynecologist clinic without symptoms of PMS or PMDD

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Ramat-Gan
country: Israel
facility: Chaim Sheba Medical Center
Study officials:
affiliation: Tel Aviv University
name: Joseph Zohar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03195946: Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes
Official title: Interventional, Open-label, Multiple-dose Study to Investigate the Effects of Multiple Doses of Lu AF35700 on the Pharmacokinetics of Cytochrome P450 (CYP450) Substrates Dextromethorphan (CYP2D6), Caffeine (CYP1A2), Omeprazole (CYP2C19), and Midazolam (CYP3A4/5) in Healthy Young Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Drug Reactions
Lead sponsor: H. Lundbeck A/S
Sponsor class: INDUSTRY
First posted: 2017-06-22
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will help determine which types of drugs that may interact with Lu AF35700


Eligibility criteria: Inclusion Criteria:

* Body weight at least 50 kg and Body Mass Index 19 - 30 kg/m2
* Good general health ascertained by a detailed medical history, laboratory tests and physical examination

Exclusion Criteria:

-Pregnant or lactating women

Other protocol defined inclusion and exclusion criteria may apply

Primary outcomes:
measure: AUC(0-inf): Area under the plasma concentration-time curve from zero to infinity
timeFrame: Up to 24 hours post dose on the following days: Day 1 and 27 for oral midazolam. Day 2 and 28 for cocktail components.
measure: Cmax: Maximum observed concentration
timeFrame: Up to 24 hours post dose on the following days: Day 1 and 27 for oral midazolam. Day 2 and 28 for Cocktail components.
Secondary outcomes:
Other outcomes:
Locations:
city: Leeds
country: United Kingdom
facility: Covance Clinical Research Unit Ltd
Study officials:
affiliation: LundbeckClinicalTrials@Lundbeck.com
name: Email contact via H. Lundbeck A/S
role: STUDY_DIRECTOR
References:
Clinical trial NCT01862146: Arterial Remodeling in Smokers
Official title: Response-to-injury in Patients Undergoing Transradial Coronary Angiography: Arterial Remodeling in Smokers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: FMD
IMT
Smoking
Keywords: TCA
FMD
IMT
Smoking
Lead sponsor: Heinrich-Heine University, Duesseldorf
Sponsor class: OTHER
First posted: 2013-05-24
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all subjects who underwent an TCA (trans radial catheterisation)

Brief summary: Cigarette smoking is the most important modifiable cardiovascular risk factor leading to endothelial dysfunction and was suggested to impair arterial regeneration.The aim of the study was to investigate the effect of smoking on vascular response to transradial coronary angiography (TCA).


Eligibility criteria: Inclusion Criteria:

* all subjects underwent a TCA

Exclusion Criteria:

* acute inflammation cardiac arrhythmia renal failure heart failure (NYHA II-IV) CRP \> 1 mg/dl malignant disease

Primary outcomes:
measure: IMT hyperplasia
timeFrame: change in radials IMT after 6-14 month after a TCA
Secondary outcomes:
measure: Endothelial function
timeFrame: change in flow mediated dilatation after 10-14 months
Other outcomes:
measure: cell migration
timeFrame: baseline
measure: Regeneration
timeFrame: baseline
Locations:
city: Duesseldorf
country: Germany
facility: Division of Cardiology, Pulmonology and Vascular Medicine Duesseldorf,
state: NRW
Study officials:
affiliation: Division of Cardiology, Pulmonology and Vascular Medicine
name: Christian Heiss, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Division of Cardiology, Pulmonology and Vascular Medicine
name: Malte Kelm, MD
role: STUDY_CHAIR
References:
Clinical trial NCT01249846: The Efficacy and Safety of 2.5 mg Chlorhexidine Gluconate Chip (PerioChip®) in Frequent Treatment Versus Routine Treatment in Therapy of Adult Chronic Periodontitis
Official title: The Efficacy and Safety of 2.5 mg Chlorhexidine Gluconate Chip (PerioChip®) in Frequent Treatment Versus Routine Treatment in Therapy of Adult Chronic Periodontitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Generalized Adult Periodontitis
Lead sponsor: Dexcel Pharma Technologies Ltd.
Sponsor class: INDUSTRY
First posted: 2010-11-30
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy and the safety of Chlorhexidine Gluconate Chip (PerioChip®) in frequent treatment versus routine treatment in therapy of adult chronic periodontitis.


Eligibility criteria: Inclusion Criteria:

1. Signed and dated Informed Consent Form.
2. Good general health.
3. Male or female patients aged \>21 years old.
4. Availability for the 25 week duration of the study.
5. Chronic periodontal disease on natural teeth
6. Females of childbearing potential must be non-pregnant and non-lactating at entry and agree to use an adequate method of birth control during the study.

Exclusion Criteria:

1. Oral health or factor that may influence the outcome of the study.
2. History of allergy to Chlorhexidine .
3. Patient uses Chlorhexidine oral rinses/mouthwashes on a regular basis.
4. Patients treated with medications that may influence the outcome of the study.
5. Presence of any of the following conditions: Type 1 diabetes, un-controlled type II diabetes, major recurrent aphtae stomatitis, abscesses and related oral pathologies.
6. The presence of any medical or psychiatric condition or any other condition that, in the opinion of the Investigator, could affect the successful participation of the patient in the study.
7. Patient participates in any other clinical study 30 days prior to the start of the study and throughout the study duration.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Department of Periodontology, School of Graduate Dentistry, Rambam Health Care Center
Study officials:
References: